ALK and colorectal carcinoma: Interestingly, this study also showed that 6 of 28 patients with CRC (21.4%) had targetable or potentially targetable gene rearrangements such as NTRK1 (n=2), RET (n=1), ALK (n=1), ROS1 (n=1), and EGFR (n=1) fusions.